Entresto improved measures of heart structure and function in HFrEF patients in new Novartis study; additional data complement findings novartis.com ↗
2019-09-01
Novartis Pharmaceuticals
Novartis PARAGON-HF trial suggests Entresto® benefit in HFpEF patients but narrowly misses primary endpoint novartis.com ↗
2019-08-19
Novartis Pharmaceuticals
Novartis to present new Entresto HFpEF and HFrEF data at ESC Congress 2019 novartis.com ↗
2018-11-11
Novartis Pharmaceuticals
New Novartis study supports Entresto as foundational HFrEF therapy and in-hospital initiation in appropriate stabilized heart failure patients novartis.com ↗
2018-08-25
Novartis Pharmaceuticals
Novartis announces new data that show Entresto® (sacubitril/valsartan) can be initiated early & safely in hospitalized patients after an acute heart failure episode novartis.com ↗
2018-05-28
Novartis Pharmaceuticals
Novartis International AG: Patient-reported outcomes tool revealed significant improvement in symptom frequency and quality of life domains with Entresto® novartis.com ↗
2018-04-16
Novartis Pharmaceuticals
Novartis announces new analysis demonstrating Entresto helped preserve kidney function in patients with chronic heart failure, especially those with diabetes novartis.com ↗
2018-04-04
Novartis Pharmaceuticals
Novartis announces JAMA Cardiology publication of data showing Entresto® improves physical and social activity in HFrEF patients versus enalapril novartis.com ↗
2017-11-12
Novartis Pharmaceuticals
New Novartis Entresto® real world evidence data shows beneficial impact on quality of life in people living with heart failure novartis.com ↗
2017-03-18
Novartis Pharmaceuticals
New analysis shows Novartis Entresto improves glycemic control in reduced ejection fraction heart failure patients with diabetes novartis.com ↗
2016-11-15
Novartis Pharmaceuticals
New analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths novartis.com ↗
2016-09-19
Novartis Pharmaceuticals
Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients novartis.com ↗
2016-06-22
Novartis Pharmaceuticals
Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology novartis.com ↗
2016-05-21
Novartis Pharmaceuticals
Novartis' Entresto® given strong Class I recommendation in both US and EU heart failure guidelines, less than a year after regulatory approvals novartis.com ↗
2016-05-19
Novartis Pharmaceuticals
Novartis announces investment in FortiHFy clinical program of Entresto® and heart failure novartis.com ↗
2016-04-02
Novartis Pharmaceuticals
New analyses show Novartis' Entresto(TM) reduced cardiovascular death or hospitalization for heart failure, consistently benefitting patients with reduced ejection fraction regardless... novartis.com ↗
2015-11-24
Novartis Pharmaceuticals
Novartis' heart failure medicine Entresto(TM) receives EU approval novartis.com ↗
2015-09-25
Novartis Pharmaceuticals
Novartis' new heart failure medicine Entresto(TM) recommended by CHMP for EU approval novartis.com ↗
2015-09-18
Novartis Pharmaceuticals
Swissmedic approves Novartis' new heart failure medicine Entresto(TM) novartis.com ↗
2015-07-07
Novartis Pharmaceuticals
Novartis' new heart failure medicine LCZ696, now called Entresto(TM), approved by FDA to reduce risk of cardiovascular death and heart failure hospitalization novartis.com ↗
Evidence & citations 3 cited values
Every value below carries the sentence it was read from.
2 sources stand behind the page.
Field
Value
Cited text
Known as
sacubitril/valsartan
“Adults with hypertension and left ventricular hypertrophy (LVH) according to Asian sex- and age-specific thresholds on cardiovascular magnetic resonance (CMR) imaging are...” PMID 37674806 ↗Aug 2023
Known as
Entresto
“Entresto (Valsartan/sacubitril) 100mg once a day, up-titrating to 200mg or maximum 400mg to achieve target systolic blood pressure below 140 mmHg, over a duration of 52 weeks.” NCT03553810 ↗